Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
20
CARM Quote, Financials, Valuation and Earnings
Last price:
$0.04
Seasonality move
:
-21.27%
Day range:
$0.04 - $0.05
52-week range:
$0.03 - $1.27
Dividend yield:
0%
P/E ratio:
0.23x
P/S ratio:
0.03x
P/B ratio:
123.48x
Volume:
402.8K
Avg. volume:
452.5K
1-year change:
-89.69%
Market cap:
$1.8M
Revenue:
$19.6M
EPS (TTM):
$0.19
Analysts' Opinion
-
Consensus RatingCarisma Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.00, Carisma Therapeutics, Inc. has an estimated upside of 2220.19% from its current price of $0.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.04.
Fair Value
-
According to the consensus of 1 analyst, Carisma Therapeutics, Inc. has 2220.19% upside to fair value with a price target of $1.00 per share.
CARM vs. S&P 500
-
Over the past 5 trading days, Carisma Therapeutics, Inc. has underperformed the S&P 500 by -11.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Carisma Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Carisma Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Carisma Therapeutics, Inc. reported revenues of $45.3M.
Earnings Growth
-
Carisma Therapeutics, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Carisma Therapeutics, Inc. reported earnings per share of $1.07.
Enterprise value:
-211.5K
EV / Invested capital:
2.01x
Price / LTM sales:
0.03x
EV / EBIT:
-0.02x
EV / Revenue:
0.00x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.02x
Gross Profit (TTM):
$4.8M
Return On Assets:
40.2%
Net Income Margin (TTM):
15.28%
Return On Equity:
-437.23%
Return On Invested Capital:
-437.23%
Operating Margin:
96.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $14.4M | $20.3M | $52.6M | $3.4M | $45.3M | |
| Gross Profit | $10.2M | $15.5M | $4.8M | $2.6M | -- | |
| Operating Income | -$81.6M | -$66.8M | $10.8M | -$13.1M | $43.8M | |
| EBITDA | -$77.5M | -$62M | $13.4M | -$12.4M | $43.8M | |
| Diluted EPS | -$155.51 | -$1.56 | $0.19 | -$0.31 | $1.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $200.5M | $192.4M | $97.6M | $34.1M | $5.9M | |
| Total Assets | $235.7M | $199.7M | $106.8M | $42.1M | $6.6M | |
| Current Liabilities | $12.6M | $34.7M | $13M | $10.6M | $6.8M | |
| Total Liabilities | $74.7M | $34.7M | $60.5M | $53.2M | $7.4M | |
| Total Equity | $161M | $165M | $46.3M | -$11.1M | -$867K | |
| Total Debt | -- | -- | $1.9M | $1.9M | $609K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$84.6M | -$67.8M | -$22.4M | -$13M | $1.9M | |
| Cash From Investing | $75.8M | $10.3M | $687K | -- | -- | |
| Cash From Financing | $63.1M | $1.2M | -$2.4M | -$461K | -$1.1M | |
| Free Cash Flow | -$85.5M | -$68.5M | -$22.4M | -$13M | $1.9M | |
CARM
Sector
Market Cap
$1.8M
$28.4M
Price % of 52-Week High
3.39%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
26.28%
-1.49%
1-Year Price Total Return
-89.69%
-16.67%
Beta (5-Year)
1.962
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.05
200-day SMA
Sell
Level
$0.24
Bollinger Bands (100)
Sell
Level
0.04 - 0.3
Chaikin Money Flow
Buy
Level
29.5M
20-day SMA
Sell
Level
$0.05
Relative Strength Index (RSI14)
Sell
Level
41.47
ADX Line
Buy
Level
21.08
Williams %R
Buy
Level
-94.8333
50-day SMA
Sell
Level
$0.05
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
969.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-19.6523)
Sell
CA Score
(Annual)
Level (-7.3568)
Buy
Beneish M-Score
(Annual)
Level (-2.6575)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (14.7172)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.
Stock Forecast FAQ
In the current month, CARM has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CARM average analyst price target in the past 3 months is $1.00.
-
Where Will Carisma Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Carisma Therapeutics, Inc. share price will rise to $1.00 per share over the next 12 months.
-
What Do Analysts Say About Carisma Therapeutics, Inc.?
Analysts are divided on their view about Carisma Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Carisma Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Carisma Therapeutics, Inc.'s Price Target?
The price target for Carisma Therapeutics, Inc. over the next 1-year time period is forecast to be $1.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CARM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Carisma Therapeutics, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of CARM?
You can purchase shares of Carisma Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Carisma Therapeutics, Inc. shares.
-
What Is The Carisma Therapeutics, Inc. Share Price Today?
Carisma Therapeutics, Inc. was last trading at $0.04 per share. This represents the most recent stock quote for Carisma Therapeutics, Inc.. Yesterday, Carisma Therapeutics, Inc. closed at $0.04 per share.
-
How To Buy Carisma Therapeutics, Inc. Stock Online?
In order to purchase Carisma Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CARM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CARM
Sector
P/E ratio
0.23x
23.89x
PEG ratio
--
-0.01x
P/B ratio
123.48x
1.81x
Price / LTM sales
0.03x
1.58x
Growth Metrics
CARM
Sector
Revenue growth
1236.78%
4.62%
Earnings growth
449.12%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.12
-$0.21
Profitability
CARM
Sector
Profitability FY 2024
$16.3M
$3.6M
Return on invested capital
-437.23%
-31.84%
Return on assets
40.2%
-27.96%
Return on equity
-437.23%
-37.63%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Dec
23
Estimated Next Earnings Date
Mar
24
Balance Sheet
CARM
Sector
Total cash
$2.8M
$26.4M
Short term investments
--
$25.7M
Total assets
$30.5M
$76.9M
Long term debt
$609K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
